CCR6 and psoriasis: Multiple reports describe CCR6 blockade therapies targeting pathogenic Th17 T-cells (46, 48) and show improvement in diseases such as psoriasis (47) through the inhibition of T-cell recruitment to inflammatory sites, illustrating that CCR6 blockade could be effective in treating T-cell mediated autoimmune disorders.